NCT04576377View on ClinicalTrials.gov

Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

977

Participants

Timeline

Start Date

October 5, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Influenza, Human
Interventions
BIOLOGICAL

FluBlok

Recombinant HA quadrivalent influenza vaccine (0.5mL Flublok®, Sanofi Pasteur) containing 180μg antigen, 45μg for each influenza strain included.

OTHER

Placebo

0.5mL saline placebo.

Trial Locations (1)

00000

The University of Hong Kong, Hong Kong

All Listed Sponsors
collaborator

University of Chicago

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

The University of Hong Kong

OTHER